• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白细胞介素 2(IL-2)会被肿瘤酸性 pH 环境所失活,这使得能够对其进行 pH 选择性突变体的工程改造。

IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein.

机构信息

Inserm UMR1277, CNRS UMR9020-CANTHER, Université de Lille, Lille University Hospital, Lille, France.

Division of Cell Signaling and Immunology, School of Life Sciences, University of Dundee, Dundee, UK.

出版信息

Sci Immunol. 2022 Dec 9;7(78):eade5686. doi: 10.1126/sciimmunol.ade5686. Epub 2022 Dec 2.

DOI:10.1126/sciimmunol.ade5686
PMID:36459543
Abstract

Cytokines interact with their receptors in the extracellular space to control immune responses. How the physicochemical properties of the extracellular space influence cytokine signaling is incompletely elucidated. Here, we show that the activity of interleukin-2 (IL-2), a cytokine critical to T cell immunity, is profoundly affected by pH, limiting IL-2 signaling within the acidic environment of tumors. Generation of lactic acid by tumors limits STAT5 activation, effector differentiation, and antitumor immunity by CD8 T cells and renders high-dose IL-2 therapy poorly effective. Directed evolution enabled selection of a pH-selective IL-2 mutein (Switch-2). Switch-2 binds the IL-2 receptor subunit IL-2Rα with higher affinity, triggers STAT5 activation, and drives CD8 T cell effector function more potently at acidic pH than at neutral pH. Consequently, high-dose Switch-2 therapy induces potent immune activation and tumor rejection with reduced on-target toxicity in normal tissues. Last, we show that sensitivity to pH is a generalizable property of a diverse range of cytokines with broad relevance to immunity and immunotherapy in healthy and diseased tissues.

摘要

细胞因子在细胞外空间与受体相互作用,以控制免疫反应。细胞外空间的物理化学特性如何影响细胞因子信号传递,目前还不完全清楚。在这里,我们表明白细胞介素 2(IL-2)的活性,一种对 T 细胞免疫至关重要的细胞因子,受到 pH 值的深刻影响,在肿瘤的酸性环境中限制了 IL-2 的信号传递。肿瘤产生的乳酸限制了 CD8 T 细胞中 STAT5 的激活、效应器分化和抗肿瘤免疫,并使高剂量 IL-2 治疗效果不佳。定向进化使选择 pH 选择性 IL-2 突变体(Switch-2)成为可能。Switch-2 与白细胞介素 2 受体亚单位 IL-2Rα 的结合亲和力更高,在酸性 pH 值下比中性 pH 值更能触发 STAT5 的激活,并更有效地驱动 CD8 T 细胞效应功能。因此,高剂量 Switch-2 治疗在正常组织中降低了靶毒性,同时引发了强烈的免疫激活和肿瘤排斥。最后,我们表明,对 pH 值的敏感性是一种具有广泛免疫和免疫治疗相关性的广泛细胞因子的普遍特性。

相似文献

1
IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein.白细胞介素 2(IL-2)会被肿瘤酸性 pH 环境所失活,这使得能够对其进行 pH 选择性突变体的工程改造。
Sci Immunol. 2022 Dec 9;7(78):eade5686. doi: 10.1126/sciimmunol.ade5686. Epub 2022 Dec 2.
2
MK-6, a novel not-α IL-2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance.MK-6,一种新型非-α IL-2,通过改善效应器对调节性 T 细胞的平衡来发挥强大的抗肿瘤活性。
Cancer Sci. 2021 Nov;112(11):4478-4489. doi: 10.1111/cas.15127. Epub 2021 Sep 23.
3
The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8 T lymphocyte/Treg cell balance.IL-2“无α”突变体诱导的抗肿瘤作用依赖于 CD8 T 淋巴细胞/Treg 细胞平衡的改变。
Front Immunol. 2022 Aug 17;13:974188. doi: 10.3389/fimmu.2022.974188. eCollection 2022.
4
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.一种长效的 IL-2 突变体,作为自身免疫性疾病的治疗方法,可选择性地激活和扩增调节性 T 细胞。
J Autoimmun. 2018 Dec;95:1-14. doi: 10.1016/j.jaut.2018.10.017. Epub 2018 Nov 13.
5
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.TransCon IL-2β/γ:一种新型长效前药,可持续释放 IL-2Rβ/γ 选择性 IL-2 变体,具有改善的药代动力学和有效激活细胞毒性免疫细胞的作用,用于癌症治疗。
J Immunother Cancer. 2022 Jul;10(7). doi: 10.1136/jitc-2022-004991.
6
Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v.新型靶向PD-1、活性优化的顺式作用IL-15突变体SOT201具有优于PD1-IL2v的抗肿瘤活性。
J Immunother Cancer. 2025 Apr 17;13(4):e010736. doi: 10.1136/jitc-2024-010736.
7
Proliferation and differentiation of CD8+ T cells in the absence of IL-2/15 receptor beta-chain expression or STAT5 activation.在缺乏白细胞介素-2/15受体β链表达或信号转导和转录激活因子5(STAT5)激活的情况下,CD8 + T细胞的增殖与分化
J Immunol. 2004 Sep 1;173(5):3131-9. doi: 10.4049/jimmunol.173.5.3131.
8
AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity.AWT020:一种新型融合蛋白,利用程序性死亡受体1(PD-1)阻断和白细胞介素-2(IL-2)顺式激活来增强抗肿瘤免疫力并降低毒性。
Front Immunol. 2025 Feb 18;16:1537466. doi: 10.3389/fimmu.2025.1537466. eCollection 2025.
9
STAT5 is critical to maintain effector CD8+ T cell responses.STAT5 对于维持效应性 CD8+T 细胞应答至关重要。
J Immunol. 2010 Aug 15;185(4):2116-24. doi: 10.4049/jimmunol.1000842. Epub 2010 Jul 19.
10
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.ALKs 4230:一种新型工程化的 IL-2 融合蛋白,具有改善的细胞选择性特征,可用于癌症免疫治疗。
J Immunother Cancer. 2020 Apr;8(1). doi: 10.1136/jitc-2020-000673.

引用本文的文献

1
Biomineral tablets for long-acting IL-2 immunotherapy.用于长效白细胞介素-2免疫疗法的生物矿物质片剂。
Nat Cancer. 2025 Jun 10. doi: 10.1038/s43018-025-00951-0.
2
TIM3-blockade synergizes with IL2 in alleviating intra-tumoral CD8T cell exhaustion.TIM3阻断与白细胞介素-2协同作用,减轻肿瘤内CD8 + T细胞耗竭。
Nat Commun. 2025 Jun 3;16(1):5130. doi: 10.1038/s41467-025-60463-4.
3
Loss of proton-sensing GPR4 reduces tumor progression in mouse models of colon cancer.质子感应型GPR4的缺失可降低结肠癌小鼠模型中的肿瘤进展。
Mol Oncol. 2025 May 21;19(8):2196-211. doi: 10.1002/1878-0261.70045.
4
Cytokine Couture: Designer IL2 Molecules for the Treatment of Disease.细胞因子风尚:用于疾病治疗的定制白细胞介素-2分子
Immunotargets Ther. 2025 Apr 4;14:403-431. doi: 10.2147/ITT.S500229. eCollection 2025.
5
TCR-T cell therapy for solid tumors: challenges and emerging solutions.用于实体瘤的TCR-T细胞疗法:挑战与新出现的解决方案
Front Pharmacol. 2025 Mar 10;16:1493346. doi: 10.3389/fphar.2025.1493346. eCollection 2025.
6
Microalgae-based biodegradable embolic agent for the treatment of hepatocellular carcinoma through transarterial embolization.基于微藻的可生物降解栓塞剂用于经动脉栓塞治疗肝细胞癌
J Nanobiotechnology. 2025 Mar 22;23(1):234. doi: 10.1186/s12951-025-03290-5.
7
Redirecting immune signaling with cytokine adaptors.利用细胞因子衔接蛋白重定向免疫信号传导。
Nat Commun. 2025 Mar 11;16(1):2432. doi: 10.1038/s41467-025-57681-1.
8
Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy.用于多药耐药肿瘤治疗的肿瘤微环境靶向纳米药物递送系统
Theranostics. 2025 Jan 2;15(5):1689-1714. doi: 10.7150/thno.103636. eCollection 2025.
9
Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.黑色素瘤中的肿瘤浸润淋巴细胞:从预后评估到治疗应用
Front Immunol. 2024 Dec 6;15:1497522. doi: 10.3389/fimmu.2024.1497522. eCollection 2024.
10
Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment.代谢守门员:利用肿瘤衍生代谢物优化肿瘤微环境中基于 T 细胞的免疫治疗效果。
Cell Death Dis. 2024 Oct 26;15(10):775. doi: 10.1038/s41419-024-07122-6.